AR098991A1 - Compuestos de nicotinamida sustituida con heteroarilo - Google Patents

Compuestos de nicotinamida sustituida con heteroarilo

Info

Publication number
AR098991A1
AR098991A1 ARP140104949A ARP140104949A AR098991A1 AR 098991 A1 AR098991 A1 AR 098991A1 AR P140104949 A ARP140104949 A AR P140104949A AR P140104949 A ARP140104949 A AR P140104949A AR 098991 A1 AR098991 A1 AR 098991A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluoroalkyl
nhc
ch2nhc
fluoroalkylene
Prior art date
Application number
ARP140104949A
Other languages
English (en)
Inventor
B Santella Joseph
Arunachalam Piramanayagam
V Duncia John
s gardner Daniel
Hynes John
Wu Hong
Murugesan Natesan
Sarkunam Kandhasamy
Reddy Paidi Venkatram
Kesavan Nair Satheesh
Ratna Kumar Sreekantha
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52355270&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098991(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR098991A1 publication Critical patent/AR098991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Abstract

También se describen el uso de tales compuestos como moduladores de IRAK4, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de aquel, en donde: HET es un heteroarilo seleccionado de pirazolilo, indolilo, pirrolo[2,3-b]piridinilo, pirrolo[2,3-d]pirimidinilo, pirazolo[3,4-b]piridinilo, pirazolo[3,4-d]pirimidinilo, 2,3-dihidro-1H-pirrolo[2,3-b]piridinilo, imidazo[4,5-b]piridinilo y purinilo, en donde el heteroarilo se sustituye con Rᵃ y Rᵇ; Rᵃ es H, F, Cl, Br, -CN, -OH, C₁₋₄ alquilo, C₁₋₄ fluoroalquilo, C₁₋₄ hidroxialquilo, C₁₋₄ alcoxi, -NH₂, -NH(C₁₋₄ alquilo), -N(C₁₋₄ alquilo)₂, -NH(C₁₋₄ hidroxialquilo), -NH(C₁₋₄ fluoroalquilo), -NH(C₁₋₆ hidroxi-fluoroalquilo), -C(O)NH₂, -CH₂NHC(O)(C₁₋₆ alquilo), -CH₂NHC(O)(C₁₋₆ hidroxialquilo), -CH₂NHC(O)NH(C₁₋₆ alquilo), -CH₂NHC(O)NHCH₂(fenilo), -CH₂NHC(O)N(C₁₋₄ alquilo)₂, -CH₂NHC(O)O(C₁₋₄ alquilo), -CH₂NHC(O)(C₃₋₈ cicloalquilo), -CH₂NHC(O)(tetrahidrofuranilo), -CH₂NHC(O)CH₂(C₃₋₆ cicloalquilo), -CH₂NHC(O)CH₂(tetrahidropiranilo), -CH₂NHC(O)CH₂(fenilo), -NHC(O)(C₁₋₄ alquilo), pirrolidinilo, hidroxipirrolidinilo o piridazinilo; Rᵇ es H o -NH₂; R¹ es: (i) C₁₋₆ alquilo, C₁₋₆ fluoroalquilo, C₁₋₆ hidroxialquilo, C₁₋₈ hidroxi-fluoroalquilo,-(C₁₋₆ alquilenil)O(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ deuteroalquilo), -(C₁₋₆ fluoroalquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₄ fluoroalquilenil)C(C₃₋₆ cicloalquil)₂(OH), -(C₁₋₄ alquilenil)NHC(O)(C₁₋₄ alquilenil)OC(O)(C₁₋₃ alquilo), -(C₁₋₆ alquilenil)NHS(O)₂(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)P(O)(C₁₋₄ alcoxi)₂, -(C₁₋₆ fluoroalquilenil)NH(C₁₋₄ alquilo), -(C₁₋₆ alquilenil)C(O)NH(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)C(O)NH(C₁₋₄ alquilo), -(C₁₋₆ fluoroalquilenil)C(O)NH(C₁₋₄ hidroxialquilo) o -(C₁₋₆ fluoroalquilenil)OP(O)(OH)₂; (ii) -(C₁₋₃, alquilenil)Rˣ, -(C₁₋₃ fluoroalquilenil)Rˣ, -(C₁₋₃ alquilenil)C(O)Rˣ, -(C₁₋₃ alquilenil)C(O)NHRˣ, -(C₁₋₃, fluoroalquilenil)C(O)Rˣ o CH₂CF=(tetrahidropiranilo), en donde Rˣ es un grupo cíclico seleccionado de C₃₋₆ cicloalquilo, tetrazolilo, 1,1-dioxidotetrahidrotiofenilo, 1,1-dioxidotiomorfolinilo, oxadiazolilo, piperidinilo, piperazinilo, pirrolidinilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, piridinilo, imidazolilo, morfolinilo, fenilo y triazinilo, en donde cada grupo cíclico se sustituye con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, -CH₃, -C(CH₂)₂OH, -OCH₃, -C(O)CH₂CN, -S(O)₂CH₃, -S(O)₂NH₂, -NHC(O)CH₃, -N(S(O)₂CH₃)₂, -CH₂CH₂(acetamidofenilo), -CH₂CH₂(metoxifenilo), -CH₂CH₂(sulfamoilfenilo), oxetanilo, bencilo y morfolinilo; (iii) C₃₋₆ cicloalquilo o C₄₋₆ cicloalquenilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, -CN, C₁₋₃ alquilo, C₁₋₃ alcoxi, -S(C₁₋₃ alquilo), -NO₂, -S(O)₂(C₁₋₃ alquilo), C₁₋₄ hidroxialquilo, -C(C₁₋₃ alquil)(OH)(C₃₋₆ cicloalquilo), -CH₂C(O)NH(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)(C₁₋₄ hidroxialquilo), -C(O)NH(C₁₋₃ alquilo), -C(O)NH(C₁₋₃ deuteroalquilo), -C(O)NH(C₃₋₆ cicloalquilo), -NHC(O)O(C₁₋₃ alquilo), -NHS(O)₂(C₁₋₃ alquilo), piridinilo, imidazolilo, pirazolilo, metilimidazolilo, metilpirazolilo y tiazolilo; (iv) tetrahidropiranilo, piperidinilo, pirazolilo, fenilo, piridinilo o pirimidinilo, cada uno sustituido con 0 a 1 sustituyente seleccionado de -OH, C₁₋₃ alquilo, C₁₋₃ fluoroalquilo, C₁₋₄ hidroxialquilo, C₁₋₃ alcoxi, -C(O)(C₁₋₄ alquilo), -S(O)₂(C₁₋₄ alquilo), -S(O)₂NH(C₁₋₄ alquilo), -NH(C₁₋₃ alquilo), -N(C₁₋₃ alquilo)₂, -O(C₁₋₃ alquilenil)N(C₁₋₃ alquilo)₂, -CH₂(morfolinilo), acetidinilo, oxetanilo, tetrahidropiranilo, morfolinilo, piperazinilo, piperidinilo, metilpiperazinilo, metoxipiperidinilo, piridinilo, pirimidinilo, metilsulfonilo acetidinilo y -C(O)(acetidinilo de metilsulfonilo); o (v) pirrolo[2,3-c]piridinilo, biciclo[2.2.1]heptan-1-ol, tetrahidrobenzo[d]tiazol-2-amina o 1,3-diazaspiro[4.5]decan-2,4-diona; y R² es (i) C₁₋₇ alquilo o C₂₋₆ alquenilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH y -CN; -(C₁₋₄ alquilenil)O(C₁₋₄ alquilo), -(C₁₋₄ alquilenil)O(C₁₋₄ fluoroalquilo), -(C₁₋₆ alquilenil)NH₂, -(C₁₋₆ alquilenil)S(O)₂(C₁₋₃ alquilo), -(C₁₋₆ fluoroalquilenil)NH(C₁₋₃ alquilo) o -(C₁₋₆ alquilenil)NHC(O)(C₁₋₄ fluoroalquilo); (ii) -(C₁₋₄ alquilenil)Rʸ, en donde Rʸ es C₃₋₆ cicloalquilo, acetidinilo, oxetanilo, oxazolilo, piridinilo, tetrahidropiranilo o morfolinilo, cada uno sustituido con o a 2 sustituyentes seleccionados independientemente de F, OH y C₁₋₃ alquilo; (iii) C₃₋₆ cicloalquilo, acetidinilo, oxetanilo, furanilo, tetrahidrofuranilo, pirrolidinilo, piperidinilo o tetrahidropiranilo, cada uno sustituido con 0 a 3 sustituyentes seleccionados independientemente de F, -OH, C₁₋₃ alquilo, C₁₋₃, hidroxialquilo, -C(O)(C₁₋₃ alquilo), -C(O)(C₁₋₃ fluoroalquilo), -C(O)(C₁₋₃ cianoalquilo), -C(O)O(C₁₋₃ alquilo), -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo), -C(O)(difluorofenilo), -NH₂, -NH(C₁₋₃ alquilo), -NH(C₁₋₃ fluoroalquilo), -NH(oxetanilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ fluoroalquilo), -NHC(O)(C₃₋₆ cicloalquilo), -NHC(O)(fluorofenilo), -S(O)₂(C₁₋₃ alquilo), imidazolilo, fenilo, pirimidinilo, fluoropirimidinilo, cloropirimidinilo y metoxipirimidinilo; (iv) adamantanilo, hidroxiadamantanilo, benzo[d]imidazolilo, benzo[d]oxazolilo, benzo[d]triazolilo, benzotiazolilo, biciclo[1.1.1]pentanilo o hidroxibiciclo[2.2.1]heptanilo; o (v) fenilo, pirazolilo, tiazolilo, tiadiazolilo o indazolilo, cada uno sustituido con 0 a 2 sustituyentes seleccionados independientemente de F, Cl, -OH, -CN, C₁₋₄ alquilo, C₁₋₄ hidroxialquilo, C₁₋₄ fluoroalquilo, C₁₋₄ cianoalquilo, C₁₋₃ alcoxi, C₃₋₆ cicloalquilo, -(C₁₋₃ alquilenil)O(C₁₋₃ alquilo), -(C₁₋₃ alquilenil)O(C₁₋₃ fluoroalquilo), -C(O)NH₂, -C(O)NH(C₁₋₃ alquilo), -NHC(O)(C₁₋₃ alquilo), -NHC(O)S(O)₂(C₁₋₃ alquilo), -S(O)₂NH₂, -S(O)₂(C₁₋₃ alquilo), pirazolilo, metilpirazolilo, imidazolilo, triazolilo, metiltetrazolilo, etiltetrazolilo, fenilo, pirimidinilo, fluoropirimidinilo y tetrahidropiranilo.
ARP140104949A 2014-01-03 2014-12-29 Compuestos de nicotinamida sustituida con heteroarilo AR098991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03

Publications (1)

Publication Number Publication Date
AR098991A1 true AR098991A1 (es) 2016-06-22

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104949A AR098991A1 (es) 2014-01-03 2014-12-29 Compuestos de nicotinamida sustituida con heteroarilo

Country Status (21)

Country Link
US (1) US9169252B2 (es)
EP (1) EP3089973B1 (es)
JP (1) JP6475252B2 (es)
KR (1) KR20160101191A (es)
CN (1) CN106061967B (es)
AR (1) AR098991A1 (es)
AU (1) AU2015204045A1 (es)
CA (1) CA2935329A1 (es)
CL (1) CL2016001706A1 (es)
EA (1) EA201691343A1 (es)
ES (1) ES2804707T3 (es)
IL (1) IL246474A0 (es)
MA (1) MA39162A1 (es)
MX (1) MX2016008723A (es)
PE (1) PE20161292A1 (es)
PH (1) PH12016501164A1 (es)
SG (1) SG11201605340QA (es)
TN (1) TN2016000271A1 (es)
TW (1) TW201609693A (es)
UY (1) UY35935A (es)
WO (1) WO2015103453A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922840B1 (en) 2012-11-08 2016-12-21 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
JP6204484B2 (ja) 2012-11-08 2017-09-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
PT3089971T (pt) * 2014-01-01 2020-09-03 Medivation Tech Llc Compostos e métodos de utilização
JP6843775B2 (ja) 2015-06-24 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
US10618903B2 (en) 2015-06-24 2020-04-14 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JOP20180011A1 (ar) * 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
BR112020005174A2 (pt) 2017-09-14 2020-11-10 Daiichi Sankyo Company,Limited composto que possui estrutura cíclica
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
CA3076613A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
BR112020012997A2 (pt) 2017-12-26 2020-12-01 Kymera Therapeutics, Inc. degradadores de irak e usos dos mesmos
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TW202136268A (zh) 2018-07-13 2021-10-01 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2023008973A1 (ko) * 2021-07-29 2023-02-02 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
US11976071B2 (en) 2021-08-18 2024-05-07 Gilead Sciences, Inc. Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP4541695B2 (ja) 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
CA2490888C (en) 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
EP1651636A1 (en) 2003-07-10 2006-05-03 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
MX2011005621A (es) * 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
WO2010144647A1 (en) * 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
EP2702064A4 (en) 2011-04-29 2014-10-08 Icahn School Med Mount Sinai Kinase Inhibitors
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
JP6096219B2 (ja) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的***取代的吡啶化合物
US9242975B2 (en) 2012-01-13 2016-01-26 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
JP6204484B2 (ja) 2012-11-08 2017-09-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物
EP2922840B1 (en) 2012-11-08 2016-12-21 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
MX2015005272A (es) 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).

Also Published As

Publication number Publication date
TN2016000271A1 (en) 2017-10-06
CN106061967B (zh) 2019-04-19
SG11201605340QA (en) 2016-07-28
EP3089973A1 (en) 2016-11-09
CA2935329A1 (en) 2015-07-09
UY35935A (es) 2015-06-30
MX2016008723A (es) 2016-09-07
IL246474A0 (en) 2016-08-31
US9169252B2 (en) 2015-10-27
WO2015103453A1 (en) 2015-07-09
JP6475252B2 (ja) 2019-02-27
AU2015204045A1 (en) 2016-08-18
EP3089973B1 (en) 2020-04-29
CL2016001706A1 (es) 2017-02-10
KR20160101191A (ko) 2016-08-24
PE20161292A1 (es) 2016-11-23
TW201609693A (zh) 2016-03-16
EA201691343A1 (ru) 2016-11-30
MA39162A1 (fr) 2017-12-29
JP2017501202A (ja) 2017-01-12
PH12016501164A1 (en) 2016-08-15
US20150191464A1 (en) 2015-07-09
ES2804707T3 (es) 2021-02-09
CN106061967A (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
AR098991A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR105113A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR100340A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR110421A1 (es) Derivados de pirazol como inhibidores de malt1
AR107714A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
AR105114A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR108875A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR095280A1 (es) Derivados heterocíclicos de imidazo[1,2-a]piridina
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR105112A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR085203A1 (es) Inhibidores benzimidazol del virus sincitial respiratorio
AR086817A1 (es) Compuestos inhibidores de la fosfodiesterasa tipo 10a
AR112264A1 (es) Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR111807A1 (es) Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
AR111808A1 (es) Derivados de pirimidina como moduladores del receptor de pge2
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii

Legal Events

Date Code Title Description
FB Suspension of granting procedure